Ann Gils, PharmD, Ph.D.
Ann Gils (°18/03/1971) graduated in 1993 as a Pharmacist at the University of Leuven (KU Leuven). She obtained her PhD in Pharmaceutical Sciences at KU Leuven in 1997. Subsequently, she worked as a post-doctoral researcher at KU Leuven/Boehringer Ingelheim (Biberach, Germany), the Academic Hospital of Maastricht (The Netherlands), and KU Leuven. She was appointed as an associate professor at the Faculty of Pharmaceutical Sciences of KU Leuven in 2006, became a professor in 2010 and a full professor in 2015.
Currently she is the principal investigator of the Therapeutic Drug Monitoring group of the Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium.
She has developed and validated a number of ELISAs to measure the serum and anti-drug antibody concentrations of biologicals (infliximab, adalimumab, etanercept, golimumab, vedolizumab, ustekinumab and secukinumab) and has participated in TDM studies in the field of gastroenterology, dermatology and rheumatology. Currently, the effect of covariates on pharmacokinetics (PK) and pharmacodynamics (PD) of biologicals is evaluated through PK/PD modeling. She has published more than 250 papers in the field of thrombosis and therapeutic drug monitoring of biologicals. Through KU Leuven she has licensed 7 ELISA to apDia (Turnhout, Belgium) and 2 lateral flow assays to R-Biopharm (Darmstadt Germany) for therapeutic drug monitoring. She holds one patent entitled dual targeting of TAFI and PAI-1 (UZ2017/0253664A2) in the field of thrombosis and haemostasis.